Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Giora Sharf - Can we safely stop TKI therapies? Experience from the STOP trials (2)

Non-adherence of CML patients

Results of the global adherence survey of the CML Advocates Network
Giora Sharf, CML Advocates Network

 

Issues covered:

  • Results of the global adherence survey of 2546 CML patients from 79 countries
  • Intentional and non-intentional non-adherence levels
  • Differences between countries, type of TKI, administration schedule, age groups, perception of quality of life and side effects
  • Tools to drive adherence and importance of routine

 

Click on the "Play" button below to hear the slidecast. Be sure to turn on your speakers to hear the audio!

 


Please share your feedback below, and view the other Virtual Education Program modules.

 

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

Has this been helpful? Please provide your comments here:

Jorge Cortes - New Drugs in the Treatment of CML

New Drugs in the Treatment of CML

Jorge Cortes, MD Anderson Cancer Center, USA

Please click on the image below to watch the webcast, and a window will open. You can then also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

 

webcast-button
edut-cortes 260

 

Issues covered

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

Jerry Radich - Transplantation for CML in 2011: Who, why, when?

Transplantation for CML in 2011: Who, why, when?

Jerry Radich, Fred Hutchinson Cancer Research Center, Seattle, USA

Please wait as the educational presentation will start automatically. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

 

webcast-button
vep jerryradich

 

Issues covered

  • The role of transplantation in 2011
  • Who should be transplanted
  • When they should be transplanted
  • Why they should be transplanted

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

Delphine Rea - Can we safely stop TKI therapies? Experience from the STOP trials

Can we safely stop TKI therapies? Experience from the STOP trials

Delphine Rea, Hôpital Saint-Louis, Paris, France

Please wait as the educational presentation will start automatically. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

 

webcast-button
delphine-rea

 

Issues covered

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib

Susan Branford - The importance of BCR-ABL kinase domain mutation analysis in CML

The importance of BCR-ABL kinase domain
mutation analysis in CML

Susan Branford, University of Adelaide, Australia

Please click on the image below to watch the webcast, and a window will open. You can then also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

 

webcast-button
vep branford mutationanalysis

 

Issues covered

  • Mutations as a mechanism of imatinib resistance
  • Why mutations arise
  • When to test for mutations
  • Therapeutic options in the presence of mutations

 

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib
  1. Susan Branford - the importance of Molecular Monitoring in CML
  2. John Goldman: CML Treatment with imatinib
  3. Michele Baccarani - European Leukemia Network (ELN) recommendations
  4. Timothy Hughes - Optimising response and managing resistance to treatment